A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
Acute Lymphoblastic Leukemia
DRUG: CODOX-M
Duration of complete remission, disease-free survival, overall survival, toxicities, 2009
The feasibility will be evaluated in terms of complete remission rate, duration of complete remission, disease-free survival, overall survival, and toxicities.